Dong-A ST creates antidiabetic agent combining ‘Suganon-Actos’
Dong-A ST has started to develop a complex combining Suganon(evogliptin), a domestic DPP-4-inhibitor treatment, and Actos(pioglitazone, Takeda Pharmaceutical), a TZD-type drug.
The Ministry of Food and Drug Safety approved the Phase 1 clinical trial of a complex combining evogliptin 5mg and piog...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
